TITLE

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

AUTHOR(S)
Davidson, Jaime A.
PUB. DATE
December 2010
SOURCE
Mayo Clinic Proceedings;Dec2010 Supplement, Vol. 85, pS27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Type 2 diabetes mellitus (DM) is a prevalent disorder that affects children, adolescents, and adults worldwide. in addition to risks of microvascular disease, patients with type 2 DM often have multiple risk factors of macrovascular disease; for example, approximately 90% of patients with type 2 DM are overweight/obese. Type 2 DM is a complex disease that involves a variety of pathophysiologic abnormalities, including insulin resistance, increased hepatic glucose production, and abnormalities in the secretion of hormones, such as insulin, glucagon, amylin, and incretins. Incretins are gut-derived peptides with a variety of glucoregulatory functions. Incretin dysfunction can be treated with glucagon-like peptide 1 (GLP-1) receptor agonists (eg, exenatide and liraglutide) or inhibitors of dipeptidyl peptidase 4 (DPP-4) (eg, sitagliptin and saxagliptin), the enzyme that degrades GLP-1. The GLP-1 receptor agonists and DPP-4 inhibitors both elevate GLP-1 activity and substantially improve glycemic control. The GLP-1 receptor agonists are more effective in lowering blood glucose and result in substantial weight loss, whereas therapy with DPP4 inhibitors lowers blood glucose levels to a lesser degree, and they are weight neutral. Treatment with GLP-1 receptor agonists has demonstrated durable glycemic control and improvement in multiple cardiovascular disease risk factors. in addition, unlike insulin or sulfonylureas, treatment with a GLP-1 receptor agonist or a DPP-4 inhibitor has not been associated with substantial hypoglycemia. These factors should be considered when selecting monotherapy or elements of combination therapy for patients with type 2 DM who are overweight/obese, for patients who have experienced hypoglycemia with other agents, and when achieving glycemic targets is difficult.
ACCESSION #
60684522

 

Related Articles

  • Incretin-Based Therapy of Type 2 Diabetes Mellitus. Knop, Filip K.; Vilsb�ll, Tina; Holst, Jens J. // Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p46 

    This review article focuses on the therapeutic potential of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in treating type 2 diabetes mellitus (T2DM). T2DM is characterized by insulin resistance, impaired glucose-induced insulin...

  • GLP-1-Based Therapy for Diabetes: What You Do Hot Know Can Hurt You. Butler, Peter C.; Dry, Sarah; Elashoff, Robert // Diabetes Care;Feb2010, Vol. 33 Issue 2, p453 

    The authors focus on a study which suggests that glucagon-like peptide 1 (GLP-1) class of drugs has a good safety profile and is appropriate for an early treatment choice for type 2 diabetes. They discuss the risk profile of GLP-1 drugs. They note that there are concerns that GLP-1 class of...

  • Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. Hoist, Jens Juul; McGill, Maria A. // Clinical Drug Investigation;2012, Vol. 32 Issue 1, p1 

    Type 2 diabetes mellitus is associated with a progressive decline in insulinproducing pancreatic P-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity. The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)...

  • CNTO736, a Novel GLP-1 Analogue, Ameliorates Insulin Resistance and Reduces VLDL Production in High-Fat-Fed C57B1/6 Mice. Parlevliet, Edwin T.; SchröDer-Van Der Elst, Janny P.; Corssmit, Eleonora P.; Picha, Kristen; O'Neil, Karyn; Stojanovic-Susulic, Vedrana; Ort, Tatiana; Havekes, Louis M.; Romijn, Johannes A.; Pijl, Hanno // Diabetes;Jun2007 Supplement 1, Vol. 56, pA374 

    CNTO736 (C) is a GLP-1 Mimetibodyâ„¢ that incorporates a GLP-1 peptide analogue genetically fused to a domain that includes the Fc portion of an antibody. The C Mimetibody was developed with the goal of providing sustained exposure of GLP-1 in patients with Type 2 diabetes (DM2). To evaluate...

  • Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies. BEST, JENNIE H.; HOOGWERF, BYRON J.; HERMAN, WILLIAM H.; PELLETIER, ELISE M.; SMITH, DANIEL B.; WENTEN, MADE; HUSSEIN, MOHAMED A. // Diabetes Care;Jan2011, Vol. 34 Issue 1, p90 

    OBJECTIVE-- To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s). RESEARCH DESIGN AND METHODS-- A retrospective database analysis was performed of...

  • A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: A glucagon-like peptide-1 analog. Hasan Abdi, Sayed Aliul; Alam, Md Shamshir; Kalam, Najmi Abul; Shobha, Churi; Shafique, Ahmed; Maksood, Ali // International Journal of Medicine & Public Health;Apr-Jun2014, Vol. 4 Issue 2, p141 

    Diabetes is leading cause for cardiovascular complication, drugs having cardioprotective and antihyperglycemic actions are constantly in search. Oral glucose elicits a three to four times higher peak insulin response compared with an equivalent dose of glucose, if infused intravenously. This is...

  • Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes. Vidal, Josep // European Endocrinology;Autumn2013, Vol. 9 Issue 2, p76 

    Optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. However, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). Almost half of patients treated with basal insulin and oral anti-diabetic...

  • Projecting the Long-Term Clinical Benefits of Treatment with the GLP-1 Analogue Liraglutide in Subjects with Type 2 Diabetes. Valentine, William J.; Hammer, Mette; Palmer, Andrew J.; Ray, Joshua A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA568 

    An international, 14-week phase 2b clinical trial with type 2 diabetes treated with diet or monotherapy reported improved glyceamic control with different doses of liraglutide compared to placebo. Liraglutide, a once daily GLP-1 analogue, was associated with improvements in HbA1c between 1.27%...

  • New GLP-1 analogs, mimetics in the pipeline for type 2 diabetes. Volansky, Rob // Endocrine Today;May2009, Vol. 7 Issue 7, p1 

    The article reports on the possibility that several glucagon-like peptide-1 (GLP-1) analogs and mimetics may become available in the market with different options for the treatment of type 2 diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics